Immune Checkpoint Inhibitor–Induced Vitiligo-Like Depigmentation
Michela Starace, Stephano Cedirian, Luca Rapparini, Alessandro Pileri, C. Carrera, Priscila Giavedoni, Mariana Lopez Leon, Lukas Kraehenbuehl, Yannick S. Elshot, Zoé Apalla, Chryssoula Papegeorgiou, Vasiliki Nikolaou, Tatjana Radević, Zsuzsanna Lengyel, Pietro Sollena, Ketty Peris, Ernesto Rossi, Davide Fattore, Dimitra Koumaki, Aram Boada, Ana‐Maria Forsea, Sònia Segura, Azael Freites‐Martínez, Julia Riganti, Emily Avitan‐Hersh, Nada Saffuri, L. Peuvrel, F. Dezoteux, Bianca Maria Piraccini, V. Sibaud
Abstract
This retrospective case series compares vitiligo resulting from immune checkpoint inhibitor (ICI) therapy vs preexisting vitiligo among patients receiving ICI treatment for cancer.
Topics & Concepts
VitiligoMedicineDepigmentationDermatologyNivolumabImmune systemProgrammed cell death 1Immune checkpointRetrospective cohort studyImmunologyInternal medicineImmunotherapyPD-L1Melanoma and MAPK Pathwaysmelanin and skin pigmentationCancer Immunotherapy and Biomarkers